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EndopredictGene expression profiles with prognostic capacities have shown good performance in multiple clinical
trials. However, with multiple assays available and numerous types of validation studies performed,
the added value for daily clinical practice is still unclear. In Europe, the MammaPrint, OncotypeDX,
PAM50/Prosigna and Endopredict assays are commercially available. In this systematic review, we aim
to assess these assays on four important criteria: Assay development and methodology, clinical valida-
tion, clinical utility and economic value.
We performed a literature search covering PubMed, Embase, Web of Science and Cochrane, for studies
related to one or more of the four selected assays.
We identified 147 papers for inclusion in this review. MammaPrint and OncotypeDX both have evi-
dence available, including level IA clinical trial results for both assays. Both assays provide prognostic
information. Predictive value has only been shown for OncotypeDX. In the clinical utility studies, a higher
reduction in chemotherapy was achieved by OncotypeDX, although the number of available studies differ
considerably between tests. On average, economic evaluations estimate that genomic testing results in a
moderate increase in total costs, but that these costs are acceptable in relation to the expected improved
patient outcome. PAM50/prosigna and EndoPredict showed comparable prognostic capacities, but with
less economical and clinical utility studies. Furthermore, for these assays no level IA trial data are avail-
able yet.
In summary, all assays have shown excellent prognostic capacities. The differences in the quantity and
quality of evidence are discussed. Future studies shall focus on the selection of appropriate subgroups for
testing and long-term outcome of validation trials, in order to determine the place of these assays in daily
clinical practice.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
In the past decades, there has been a steady increase in the sur-
vival rates of patients with breast cancer. Among other factors like
early screening and awareness, the majority of this effect is attrib-
uted to the concept of adjuvant therapy [1,2]. However, among all
patients receiving adjuvant chemotherapy, the majority would not
have developed metastases even without adjuvant therapy,
whereas in contrast some patients without the indication for adju-
vant therapy still develop distant metastases. A recent progress inthis optimal selection is the development of genomic profiling
assays [3]. We chose four crucial criteria for determining the value
of these assays.Assay development and methodology
The first criterion is the methodological robustness, both during
development and during the commercial activities. For example,
the tests should be validated in a cohort independent from the
training cohort, and should not be used in a patient population
in which the test was not validated unless re-validation is per-
formed. Furthermore, there should be little to no inter-test varia-
tion when the same tissue samples are tested multiple times.
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population. Therefore, studies need to focus on identifying sub-
groups which do not benefit from genomic testing since the out-
come of the test overlaps with the stratification by the
clinicopathological factors (e.g. when all or almost all triple-
negative breast cancers are considered high-risk by the test).
Clinical validation
A second important factor is the effect on clinical outcome
between the different test-outcome groups. Similar to classical
biomarkers, a distinction can be made between the prognostic
and the predictive value of a test [4]. Since the utility of genomic
testing is in particular aimed at guiding decisions regarding
chemotherapy, a predictive test, able to predict which patients
will benefit from chemotherapy or not, is more valuable than a
solely prognostic test which is only associated with the patient
prognosis.
Clinical utility
The third criterion is the clinical utility of the test. Applying the
test should lead to a shift in the indication of chemotherapy as
compared to indication based on traditional parameters. In other
words, if the patients using chemotherapy based on the test results
are exactly the same patients as the ones using chemotherapy
based on the traditional clinicopathological parameters, the test
has no additional value.
Economic value
The fourth, and last criterion for genomic testing is the eco-
nomic value of the test. Due to the commercialisation of the assays,
the tests are more expensive than the regular pathological assess-
ment, with costs ranging from €1800 to €3700 per test. In an era of
emphasis on healthcare efficiency, the costs of the test should be
justified by its clinical and health benefits, and the reduction in
costs by reducing adjuvant therapy use.
Test descriptions
The first test, which was first developed in 2002 by van
‘t Veer et al. and for which the prognostic capacities were
shown simultaneously by van de Vijver et al., is the 70-gene
prognosis profile, better known as MammaPrint (Agendia BV,
Amsterdam, The Netherlands) [5,6]. This assay uses the mRNA
expression of 70 genes using microarray technology, to catego-
rize patients in either a low or high risk. These 70 genes were
identified from a total of 25,000 genes using supervised
clustering.
The second test in this review is the 21-gene Recurrence Score,
also known as the OncotypeDX Recurrence Score (RS) (Genomic
Health Inc., Redwood City, CA). The test is based on the expression
of 21 genes in FFPE cancer tissue, determined using reverse tran-
scriptase PCR (RT-PCR) [7]. Of these genes, 16 genes are cancer-
related and were selected out of 250 rationally selected candidate
genes based on their prognostic capacity and consistency in test
performances [7]. Based on these relative expressions, the Recur-
rence Score is calculated ranging from 0 to 100, with low risk rang-
ing from 0 to 17, intermediate risk ranging from 18 to 30, and high
risk ranging from 31 to 100. However, for the most important val-
idation trial of this test, the risk categories in this trial were
adjusted to 0–10, 11–25 and 26–100 for the low-, intermediate-
and high risk respectively [8].
The third test included in this review is the Prosigna, based on
the better-known PAM50 test (NanoString Technologies, Seattle,WA). This test, based on the expression of 46 genes using
quantitative PCR (qPCR) is able to distinguish between the molec-
ular subtypes of breast cancer (luminal A, luminal B, HER2-
enriched, normal-like and basal-like) [9]. Furthermore, it provides
the risk of recurrence score (ROR) and the subsequent risk cate-
gory. The test was adapted by NanoString in order to allow the
use in local pathology laboratories [10].
The fourth and last test which will be discussed in this system-
atic review is the EndoPredict (Myriad Genetics Inc, Salt Lake City,
UT). This assay uses the expression of 8 cancer-related and 3 refer-
ence genes determined by RT-PCR, which results in a risk score
from 0 to 15 (EP), which is subsequently divided into low and high
risk [11]. A special feature of the EndoPredict is the integration of
tumor size and nodal status, resulting in an EP clinical score
(EPclin). The EndoPredict can be performed in local laboratories,
in contrast to the MammaPrint and OncotypeDX which are cen-
trally determined and therefore need more elaborate logistical
planning.
In this review, we evaluate four genomic assays available in
Europe using a systematic evaluation focusing on all four major cri-
teria with the aim to assess each test individually for its strengths
and weaknesses.Methods
Search strategy
This systematic review was to comprehensively cover all
four aspects of the four commercially available genomic profil-
ing tests in Europe on four different aspects: developmental
and methodological robustness, extend of clinical validation,
clinical utility and economic value. These items were chosen
after a consensus meeting and cover those evaluation criteria
we deemed most important. We searched PubMed, Embase,
Web of Science and Cochrane for articles published before
April 2016. The search strategy (supplementary document 1)
was applied on April 7th 2016, and after evaluation of all
abstracts it was updated at September 9th 2016. Abstracts
were screened for relevance based on the title and abstract,
and remaining full-text articles were screened based on the
inclusion criteria.Selection criteria
Articles were selected if they studied one of the four tests
available in Europe: OncotypeDX, MammaPrint, Prosigna or
Endopredict. Furthermore, the article should be original peer-
reviewed research; abstracts, posters, reviews and meta-
analyses were excluded. The article needed to cover one of the
four criteria: development of the test, clinical validation, clinical
utility or an economical evaluation. For the clinical validation
studies, survival analysis was required, evaluating either the dif-
ferences in survival between test-outcome groups, or the benefit
of therapy in one or more test-outcome groups. For the clinical
utility studies, decision impact studies were to be available in
a representative cohort, and had to report both the absolute
increase or decrease in chemotherapy as well as the shift from
one treatment category to the other. Retrospective large-scale
population-based impact studies were also included, reporting
real-life shifts in the use of genomic testing and the subsequent
changes in therapy decisions. Two reviewers (EJB, EB) indepen-
dently selected articles that met the above inclusion criteria
based on title and abstracts. Next, full-texts of potentially rele-
vant articles were screened. Agreement concerning eligibility
was achieved during consensus.
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Data extraction was independently performed by the two
reviewers. Data was collected concerning the performed test,
the number of included patients, the results of the test, and
survival outcome or change in treatment where appropriate. Dis-
agreements in data extraction and interpretation were resolved
during a consensus meeting. There were no changes in eligibility
criteria during the selection of articles. All studies that fulfilled
the inclusion criteria were included, independent of their
methodological quality; no risk of bias assessment was per-
formed. Both retrospective and prospective studies were
included without exclusion of particular study designs with an
emphasis on prospective RCTs (where available). Data were
recorded in the tables as mentioned in the articles, no additional
statistics were performed. Both point estimates and 95%CI were
recorded, where appropriate and mentioned in the selected
articles.
Due to the heterogeneity of the studies chosen, the patient
selection and endpoints reported, no further statistical analyses
could be performed. Results were stratified in (1) one of the four
tests and (2) lymph node positive or lymph node negative patients
or articles where the distinction could not be made or both groups
were included.
For the clinical utility, extracted data from decision-impact
studies were pooled (weighted by the number of patients) to
give an estimate of the chemo-reduction and shift in therapy a
test can establish. We only considered a change in chemotherapy
and recorded the percentage of patients who would receive
chemotherapy before the test, and after the test (as mentioned
in the included articles). For the table on clinical validation,
the number of patients who were high or low risk according
to the test were recorded and the outcome in the groups. Out-
comes were recorded as mentioned in the articles: distant
metastasis or distant recurrence free survival, breast cancer
specific survival, and overall survival were most frequently
reported. Where known, both the point estimate and the 95%CI
were recorded. The Hazard Ratio and corresponding 95%CI for
the difference in outcome between the risk groups was recorded
if this was mentioned in the articles. For the economic review,
original evaluations were included if they compared costs
beyond the assay costs alone. Evaluations could be cost mini-
mization analyses (CMA), cost effectiveness analyses (CEA, com-
paring costs to life years) or cost utility analyses (CUA,
comparing costs to quality-adjusted life years (QALYs)). To
aggregate, QALYs were imputed for CMAs and CEAs (as predicted
by the average and the life year gain, respectively) and costs
were updated to Euros at price level 2016. When more than
one (non-) genomic strategy was included in an economic eval-
uation, the (non-) genomic strategy with the highest QALYs was
used in the review.Results
Using our search strategy, we identified 1345 unique titles and
abstracts. Limiting ourselves to the manuscripts only related to the
topics of this review, we selected 280 studies for further full-text
evaluation. From these 280 full-text manuscripts, we selected
149 papers for inclusion in this review: 11 about developmental
validation, 12 about biomarker prediction, 50 about clinical
studies, 28 about clinical utility and the effect on chemotherapy
reduction, 44 economic evaluations and 4 studies making direct
head-to-head comparisons on test outcome between two or more
of the included tests (Fig. 1).Assay development and methodology
In the development of MammaPrint, multiple evolutions were
necessary to allow high-throughput screening of FFPE tissue. Glas
et al. first converted the original research-based micro-array con-
taining approximately 25,000 probes to a mini-assay with good
concordance and reproducibility [12,13].
A second step was the conversion from frozen to FFPE tissue by
Mittempergher et al., with an R2 of 0.94 [14]. After this proof of
principle, Sapino et al. further developed the MammaPrint towards
an FFPE platform, again with a good correlation between FFPE and
frozen tissue (r = 0.92), and a high concordance between high- and
low-risk classifications between both methods (j-score 0.82) [15].
Beuner et al. validated both the conversion to a mini-assay and the
conversion from frozen tissue to FFPE retrospectively, by compar-
ing the scores of both methods [16].
Gyanchandani et al. studied whether intratumoral heterogene-
ity might influence the outcome of a gene expression test in 74 ER-
positive cases using most included gene expression panels, by
assessing different tumor regions from the same FFPE block [17].
They showed that genomic assays with a higher number of
included genes resulted in a lower rate of discordant samples.
Drury et al. studied the use of 0.6 mm cores and compared these
with full sections, to establish whether tissue-microarrays (TMAs)
could be used for genomic profiling using OncotypeDX [18].
Although the total RNA yield was lower from tissue cores com-
pared to full sections, the OncotypeDX Recurrence Score results
from individual cores clustered closely, and had an excellent corre-
lation with full-section RS (Spearman R = 0.91).
For the Endopredict, the use of pre-surgery biopsies and surgi-
cal sections from 40 ER-positive HER2-negative tumours was com-
pared. It was shown that comparing both results resulted in a
Pearson correlation coefficient of 0.92, showing that core needle
biopsies can be used for genomic profiling using Endopredict
[19]. Another aspect of the EndoPredict is decentral assessment,
meaning that every individual pathological laboratory can perform
this test and thereby reducing the logistical strain on the testing
procedure. Denkert et al. tested this decentral evaluation [20].
The Pearson correlation coefficient for all measurements was a
near-perfect 0.994, and 100% of the samples were assigned to the
same EP risk group as the reference test. Furthermore, Kronenwett
et al. showed that this decentral approach had excellent precision
and reproducibility, although with a small sample size [21].
Although these published studies showed a good reliability and
reproducibility, the MINDACT trial shows that there can be prob-
lems which hamper the reliability and feasibility of a test. Between
May 2009 and January 2010, 162 patients were falsely identified as
being high risk, due to a change in RNA-extraction solution [22].
Furthermore, of all 11,288 screened patients, there was a screening
failure in 1182 patients (10%) in which the MammaPrint was not
feasible [22].
Another concern for the reliability of test results is the ratio
between tumor and normal tissue in the tested specimen. Elloumi
et al. showed that an increase of normal tissue in the specimen
leads to biased test results when compared to uncontaminated
tumor tissue test results [23]. For the PAM50 this bias was linear,
showing a more favourable outcome with increasing normal tissue
content. For the MammaPrint and OncotypeDX the bias was unpre-
dictable, switching both from low to high risk and vice versa with
increasing normal tissue content. All tests have since developed
strategies to mitigate this bias.
A couple of studies directly compared the test results of multi-
ple tests performed on one tumor. In the OPTIMA Prelim trial,
patients were randomized between standard therapy or
OncotypeDX-directed therapy [24,25]. Among others, also Mam-
Idenfied tles and abstracts
(n=1345)
Included full-text studies (n=149)











• Outcome did not match one of the 
four criteria (n=71)
• Full-text not available (n=19)
• Wrong type of study (review, 
abstract) (n=17)
• Neo-adjuvant seng (n=9)
• Non-English (n=8)
• Other assay (n=5)
• Only locoregional outcome (n=2)
Fig. 1. A diagram showing the inclusion of relevant papers in the systematic review.
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measurements were between 0.40 and 0.53. In the same cohort
of patients, OncotypeDX predicted 17.9% to be high risk, compared
to 38.6% and 34.5% for MammaPrint and Prosigna respectively. This
pilot trial is now followed by the OPTIMA trial, in which treatment
directed by the Prosigna assay is compared with regular care. In a
smaller prospective study, 52 samples were analysed with both the
OncotypeDX and Prosigna, showing a Spearman correlation coeffi-
cient of 0.08 [26]. Remarkably, 57.1% of the patients classified as
high risk by Prosigna were classified as low risk by OncotypeDX.
In a similar study comparing Endopredict and OncotypeDX results
in 34 samples, a Pearson correlation of 0.65 was shown, with a con-
cordance between risk categories of 76% [27].
Prediction of test results
Theoretically, a genomic profile can have an excellent prognos-
tic value, but is 100% predicted by the occurrence of other markers
and therefore has no added value. Therefore, it is crucial to estab-
lish the added value of the test, by testing whether the test result
can be predicted by standard clinicopathological parameters. This
testing could identify subgroups for which the test is not valuable.
We identified 12 studies evaluating this effect, which are reported
in Table 1. In general, tumours which are (a combination of) grade
1, PR-positive and/or have a Ki-67 expression lower than 10%, are
almost always low risk when genomic testing is performed. Simi-
larly, tumours which are (a combination of) grade 3, PR-negative
and/or have a Ki-67 score of more than 40%, are almost always
high-risk. For these subgroups, genomic profiling provides little
additional information.
Clinical validation
A total of 50 studies was identified assessing the clinical ben-
efit of the genomic assays; 21 assessing the MammaPrint, 20
assessing the OncotypeDX, 5 assessing the PAM50/Prosigna and4 assessing the Endopredict. Most of the studies were retrospec-
tively stratifying the cohort in separate risk categories deter-
mined by the test, and showing a difference in either distant
metastasis-free, disease-free or overall survival. Table 2 shows
the results of the retrospective included studies, according to
test and patient inclusion. In general, the studies are difficult
to compare due to different patient inclusion and outcome mea-
sures. All published studies showed a good differentiation in
high and low risk and were associated with survival (both Dis-
tant Metastases/Recurrence Free Survival (DMFS/DRFS) as Overall
Survival (OS)). In more detail, MammaPrint was reported to be of
significant prognostic value for patients with lymph node nega-
tive breast cancer and the results of the test correlated well with
Adjuvant!, St Gallen and NIH guidelines and the NPI. For lymph
node positive disease, the hazard ratios for DMFS and Breast
Cancer Specific Survival (BCSS) showed a significant difference
in prognosis for low versus high risk according to MammaPrint.
In the remaining articles (without specific classification or LN
and LN+ combined) the MammaPrint was also of prognostic
value; most of the results showed a significant difference in out-
come between low and high risk.
With respect to OncotypeDX, most of the studies in patients
with LN negative disease studied the DRFS and showed a signifi-
cant difference in outcome between low, intermediate and high
risk patients. Paik et al. showed a statistical different effect of
chemotherapy in the three risk groups with a significant interac-
tion term between chemotherapy and the Recurrence Score. One
case-control study showed a significant difference between both
groups. Besides, the study in LN+ disease also showed a significant
interaction between the RS and clinical benefit of chemotherapy
for the first 5 years after treatment. The remaining studies (com-
bined LN and LN+ and one study in patients with metastatic dis-
ease) showed a good discrimination between the three risk groups
and a significant difference in outcome in most of the studies.
Studies that used the PAM50 showed a good discrimination,
and a significant interaction between treatment and outcome in
Table 1
Marker prediction, according to test and nodal status.
Marker prediction
Authors Year Patients (N) Markers in best-fit model R2 best fit model Subgroups little/no benefit of testing (>75% in risk category)
MammaPrint
Early stage breast cancer (combined LN- and LN+, other groups or not specified)
Cardoso*[22] 2016 NA NA Grade 1 93% low risk
Grade 3 75% high risk
ER- PR- 96% high risk
Gevensleben [28] 2010 140 NA NA St. Gallen high risk 80% high risk
St Gallen low risk 86% low risk
Grade 1 79% low risk
Grade 3 76% high risk
PR-negative 76% high risk‘‘
OncotypeDX
Lymph node negative
Chaudhary [29] 2016 350 NA NA PR+ 95% low or intermediate risk
Dialani [30] 2016 319 ER, PR, HER2, tumor grade 0.55 NA NA
Sparano*[8] 2015 8523 NA NA PR- 5% low risk
Grade 3 11% low risk
Ingoldsby [31] 2013 52 PR (allred), nuclear pleomorphism (np), survivin NA Grade 1 100% low or intermediate risk
PR <2, np-score 3 100% high risk
Sahebjam [32] 2011 53 PR, Ki-67 0.84 Ki-67 <10% 100% = low or intermediate risk
Auerbach [33] 2010 138 Mitotic count, PR NA PR+ &Mitotic count 1 or 2 100% = low or intermediate risk
PR- & Mitotic count 2 or 3 75% = high risk (0% low risk)
Flanagan [34] 2008 42 ER, PR, grade, HER2, mitotic count 0.66 Grade 1 100% low or intermediate risk
Grade 3 83.3% high risk (0% low risk)
Wolf [35] 2008 300 NA NA PR+ & Grade 1/2 94% low or intermediate risk
Early stage breast cancer (combined LN- and LN+, other groups or not specified)
Gluz [36] 2016 2642 NA NA Grade 1 90% low or intermediate risk
Ki-67 <20%, PR >20% 95% low or intermediate risk
Ki-67 >40% 90% high risk
Bradshaw [37] 2013 158 ER (allred), PR (allred), Ki-67 0.62 NA NA
Allison [38] 2012 173 PR, tumor grade Unknown (p < .001) Grade 1 & PR >5 (allred) 100% low or intermediate risk
Grade 3 & PR <5 (allred) 80% high risk (0% low risk)
Williams [39] 2011 133 NA NA Ki-67 <10% 99% = low or intermediate risk
* Not designed to predict test results, but data are provided in the manuscript.
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ies showed a significant association with distant recurrences. For
studies that used EndoPredict differences between high and low
risk were associated with outcome or showed a low proportion
of distant metastases in the low risk group.
Both the PAM50/Prosigna and EndoPredict have a quality B
level of evidence in all of their validation studies by performing
them in established clinical trials, according to Simon et al. [83]
For MammaPrint one level A trial is available [22], all other studies
are level C quality or lower. For OncotypeDX, there is a mix of two
level A trials [8,36], some level B studies showing predictive capac-
ities of OncotypeDX, and level C/D studies in retrospective or case-
control studies. All level A evidence will be discussed in the next
paragraphs.
MINDACT
The MINDACT trial evaluated the use of the MammaPrint
together with Adjuvant Online, an online tool using clinicopatho-
logical information for risk stratification [22]. Patients with discor-
dant risks based on the clinical and genomic assessment, were
randomized between chemotherapy or no chemotherapy. The pri-
mary study subgroup were the patients with a clinical high and
genomic low risk tumor who were randomly allocated to receive
no chemotherapy. The distant metastasis-free survival of this
group was 94.7% at 5 years, which was significantly higher com-
pared to a pre-determined null hypothesis of 92%. Therefore, it
was concluded that the prognosis of these clinically high-risk,
but genomic low risk patients without chemotherapy was good
enough to justify the abstention of chemotherapy.The trial is labelled as phase 3 RCT and the results are
regarded as level IA evidence. However, the design of the primary
analysis is that of a cohort study, since it only assessed the
patients who had a discordant risk and did not receive
chemotherapy. In a secondary per-protocol analysis, comparing
the c-high/g-low patients with and without chemotherapy, a HR
of around 0.65 was shown in favor of chemotherapy, which was
significant for DFS (90.3% vs 93.3%, p = .026), but not for DMFS
(94.8 vs 96.7, p = 0.106) or OS (97.3 vs 98.8, p = 0.245). In
summary, although the prognosis of this clinically high-risk group
is good without chemotherapy, it is significantly better when
receiving chemotherapy.
Another secondary outcome is the effect of chemotherapy in
patients who were clinically assessed as low-risk, but with a geno-
mic high risk profile. In this subgroup, no statistically significant
benefit of chemotherapy was observed for either DMFS (HR 0.90
95% CI 0.40–2.01), DFS (HR 0.74 95% CI 0.40–1.39) or OS (HR
0.72, 95% CI 0.23–2.24), indicating that a high-risk MammaPrint
test result does not predict an effect of chemotherapy for these
low-risk patients. Although this analysis is underpowered, and no
formal interaction test was performed, the authors conclude that
the MammaPrint failed to show its value as a predictive biomarker,
not being capable of identifying patient who would benefit from
chemotherapy.
TAILORx
The TAILORx trial was designed to assess the clinical use of
OncotypeDX to decide on the chemotherapy administration,
especially in the intermediate risk group. For this, 10,273 patients
Table 2
Clinical validation, according to test and patient inclusion.
Clinical validation
Authors Year LOE Patients (N) Low/High risk (n) Outcome HR (95%CI) Concordance
MammaPrint
Lymph node negative




NPV DM 100% (87–100)
PPV DM 12% (6 2 2)
Van ‘t Veer
[5]





Validation set 2/19 incorrect




DMFS 93% (SE 3%) vs 72% (SE 6%)
BCSS 99% (SE 1%) vs 80% (SE 5%)
DMFS 4.6 (1.8–12.0; p = .001)
BCSS 2.0 (1.0–4.0; p = .04)
Adjuvant! 62 (42%) good
prognosis;
45 (30%) poor prognosis






St. Gallen guidelines 29
(80.6%); 30 (83.4%)
NIH guidelines; 23 (63.8%)
Adjuvant! Online
























DMFS 98(±2) good vs 78(±6) poor







DMFS 86(±5) vs 50(±6)




Knauer [46] 2010 D N = 541 LN+,




BCSS 97% low vs 87% high
DMFS 95% low vs 82%
BCSS low: 97% ET, 99% ET+CT
BCSS high: 81% ET, 94% ET+CT
DDFS low: 93% ET, 99% ET+CT














OS 97% vs. 76% high risk
DMFS 87% low vs 63% high (p < .01)
HR 2.211, p = .005




DMFS 91% (SE 4%) vs 76% (SE 4%)
BCSS 96% (SE 2%) vs 76% (SE 4%)
4.13 (1.72–9.96; p = .002)
5.70 (2.01–16.23; p = .001)
Discordant Adjuvant! 77
(32%)
Early stage breast cancer (combined LN- and LN+, other groups or not specified)
Mook [49] 2010 D N = 964, pT1 Good 525
Poor 439
DMFS 87% SE 2% vs 72% SE 3%,









Mean OS 54.6(±4.4) vs 94.5(±2.6)
DMFS 85.2(±4.3) vs 50.6(±4.5)
5.1 (2.9–9.0)












25-yrs DMFS 60.4 (45.3–80.5) vs 41.6
(32.6–53.1)
25-yrs OS 57.3 (44.8–73.2)vs 39.7 (31.7–49.8)
DMFS 3.1 (2.02–4.86)
OS 2.9 (1.90–4.28)







Cardoso [22] 2016 A N = 6693 early
stage BC
Low CR-low GR 2745,
Low CR-High
GR 592, High CR-Low
GR 1550,
High CR-High GR 1806
Chemo: 95.8 (92.9–97.6)
No chemo: 95.0 (91.8–97.0)
DMFS No chemo: 94.4 (92.3–95.9)
DMFS chemo: 95.9 (94.0–97.2)
CT vs no CT: 1.17 (0.59–2.28)
CT vs no CT: 0.78 (0.50–1.21)
14.3%
















Authors Year LOE Patients (N) Low/High risk (n) Outcome HR (95%CI) Concordance







DMFS 2.32 (1.35–4.00) vs Adjuvant! 1.68
(0.92–3.07)
OS: 2.79 (1.60–4.87) vs 1.67 (0.93–2.98)




10-yrs OS: 90.2% (86.3–94.1)
65.2% (60.3–70.1)
10-yrs DMFS 87.7 (83.6–91.8) vs 64.5
(59.8–69.2)
St. gallen low risk 4, high
risk 6, intermediate 34
Kok [55] 2012 D 121 with TAM,
151 no TAM,




BCSS 80.6 (SE 4.7) vs 63.4 (SE 8.2)
BCSS 90.2 (3.3) vs 63.3 (6.3)









Multivariable 10.19 (1.05–99.01); P = .013




PPV 9.8%, NPV 100%
OncotypeDX
Lymph node negative
Toi [58] 2010 D N = 200, N0, ER+ Low 48%
Intermediate 20%
High 33%
DRFS 3.3 (1.1–10.0) vs 0% vs 24.8 (15.7–37.8)
OS 6.4 (2.9–13.6) vs 2.6 (0.4–16.8) vs 19.1
(11.3–31.3)
HR for 50-point increase 6.09 (2.17–16.7),
p < .001
Paik [7] 2004 D N = 668, N0, ER+ Low 51%
Intermediate 22%
High 27%
DRFS 6.8 (4.0–9.6) vs 14.3 (8.3–20.3) vs 30.5
(23.6–37.4)
3.21 (2.23–4.61); p < .001
Naoi [59] 2013 D N = 459, N0, ER+ Low 286
Intermediate 81
High 92
RFS better low vs intermediate p = .0014 and
high P = 1.7e-11






RS 0–10: 5-yrs invasive DFS 93.8 (92.4–94.9);
DRFS 99.3




2010 B N = 895, N0, ER+ Low 862
Intermediate 368
High 444
10-yr LRR 4.3 (2.3–6.3) low, 7.2 (3.4–11.0)
intermediate, 15.8 (10.4–21.2) high RS
Placebo: p = .022: 10.8% (5.8–15.8%) vs 20.0%
(9.9–30.0%) vs 18.4% (9.5–27.4%)
CT+TAM: p = .028; 1.6% (0–3.5%) vs 2.7%
(0–6.4%) vs 7.8% (2.6–13%)
HR 2.16 for 50 units in RS (1.26–3.68; P = .007)
Sgroi [61] 2013 B N = 665, N0, ER+ BCI vs OncotypeDX vs
IHC4
-Early DR: BCI HR 2.77 [95%CI1.63–4.70], LR-Dv2=15.42, p < 00001; 21-gene recurrence score
HR 1.80 [1.42–2.29], LR-Dv2=18.48, p < .0001; IHC4 HR 2.90 [2.01–4.18], LR-Dv2=29.14, p < .0001
-Late DR BCI HR 1.95 [95% CI 1.22–3.14], LR-Dv2=7.97, p = .0048; 21-gene recurrence score
HR 1.13 [0.82–1.56], LR-Dv2=0.48, p = .47; IHC4 HR 1.30 [0.88–1.94], LR-Dv2=1.59, p = .20)
Paik [62] 2006 B N = 651, N0, ER+ Low 353
Intermediate 134
High 164
DR: Low chemotherapy RR 1.31 (0.46–3.78),
intermediate
RR 0.61 (0.24–1.59); High RR 0.26 (0.13–0.53)
Test interaction chemotherapy and RS p = .038
Tang [63] 2011 B N = 1444 N0, ER+ Intermediate RSPC
(17.8%)
DR vs RS RSPC vs RS: intermediate 17.8 vs
26.7, and low risk 63.8 vs 54.2
Interaction term RSPC chemotherapy p = .10
Yorozuya
[64]
2010 D N = 40, N0, ER+,
Stage I-IIA
Cases 10, controls 30.
Cases: low 3,
intermediate 1, high 6;
Controls low 19,
interm 8, high 3
Mean RS cases 40.0 (21.1–58.9), controls 17.8
(13.8–21.9); p < .001
Lymph node positive





DFS TAM alone HR 2.64 (1.33–5.27) 50point
difference. Benefit chemotherapy low risk: HR
0.97 (0.54–1.93), high risk HR 0.59 (0.35–1.01)
Interaction RS treatment p = .029 1 st 5 yrs,
















Authors Year LOE Patients (N) Low/High risk (n) Outcome HR (95%CI) Concordance
Early stage breast cancer (combined LN- and LN+, other groups or not specified)





3-yrs DFS 98% RS<=11, 96% RS 12–25, 92% RS
> 25
Dowsett [66] 2010 B N = 1231, HR+,
postmenopausal
N0: 59, 26, 15%
N+: 52, 31, 17
9-yr DR 4%, 12% and 25% in N0
9-yr DR 17%, 28% and 49% in N+
RS 50 units: N0: 5.25(2.84–9.73), N+3.47
(1.64–7.38)
Cuzick [67] 2011 B N = 1125, ER+ DR RS vs IHC4 score (r = 0.68 for TTDR, N0;
r = 0.71 for time to recurrence [TTR], all;









5-yr recurrence rate low risk: 0–1 positive
nodes 3.3 (2.2–5.0), 2-3positive nodes: 7.9%
(4.3–14.1)
Multivariable – 50-point increase) 2.12
(0.97–1.65)





DDFS: RS predictor DDFS p < .001. High RS
76.4% (59.2–87.1), low RS 95.9%(93.0–97.6)
HR 2.197 (0.901–5.356), p = .083
Tang [70] 2010 B N = 668 Low: 338
Intermediate 149
High 181
Adjuvant! Low: DRFS 5.6 low, 10%
intermediate risk, 18.2% high. Adjuvant!
Intermediate: 13.4, 13.9, 43.2. Adjuvant!
High: 5, 23.4, 31.5%
CT interaction P = .031 DRFS, P = .011 OS,
P = .082 DFS,
Concordance with
Adjuvant! 0.49,Adjuvant!
OS interaction CT p = .009,











Aktas [72] 2013 D N = 68, HER2- Low 30
Intermediate 29
High 9
Correlation RS – PR p =
.006, with G3 p = .002, low
Ki67 p < .001







RS and NPI r = -0.0737, p =
.4527




78-gene TAM response, Oncotype DX and
HOXB13-IL17BRratio-TTP:HR 2.2 (1.3–3.7,
P = .005),2.3 (1.3–4.0, P = .003) & 4.2
(1.4–12.3, P = .009)
Multivariable model 1.94 (1.01–3.73); p = .048 Concordance 45–61%
PAM50/Prosigna
Martin [75] 2013 B N = 820 OS low PAM50 HR 0.23 (0.09–0.57), p < .001 Interaction PAM50-treatment: p = .006 cont.
p = .019 groups






Higher ROR worse RFS p = .03. Multivariable
ROR high vs low/int HR 1.98 (0.53–7.45;
p = .311)
Subtypes p = .002 multivariable model. Not
predictive treatment effect p-interaction = 0.23
Sestak [77] 2015 B N = 2137, HR+,
postmenopausal
DR High risk: 16.6 (13.1–20.9), intermediate
8.3 (6.1–11.2), low 2.4 (1.6–3.5). HR high 6.9
(4.54–10.47), intermediate HR 3.26
(2.07–5.13) compared to low
Added to clinical factors: Univariable
LRchi2 = 67.94; Multivariable LRchi2 = 35.25
r = 0.36





DR ROR HR 1.03 (1.02–1.04, P < .0001);
log-likelihood test:
DLRv2 = 53.49; P < .0001
DRFS 10-yrs low risk 96.7 (94.6–98.0,
intermediate 91.3% (88.1–93.8), high 79.9%
(75.7–83.4)
Spearman’s correlation
coefficient: 0.32, P < .0001
Filipits [79] 2014 B N = 1246 Low 460
Intermediate 416
High 370
Late DRFS compared to clinical factors: DLRc2
15.32, P < .001. 15-yrs DRFS low 97.6
(94.7–98.9), intermediate 90.9 (85.9–94.2),
high 82.5 (74.8–88.1)









































































































































































































































































































































































































































































































































































































































































82 E.J. Blok et al. / Cancer Treatment Reviews 62 (2018) 74–90were enrolled, who all had ER and/or PR-positive, node-negative
disease but did have an indication for chemotherapy based on the
NCCN-guidelines. Low-risk patients (based on Recurrence Score)
received endocrine therapy only; high risk patients received both
endocrine and chemotherapy. Intermediate risk-group patients
were randomly allocated to either endocrine therapy alone or a
combination of endocrine and chemotherapy. Until now, only the
results of the low-risk patients were published [8].
A total number of 1626 patients with a low-risk OncotypeDX
test received no chemotherapy. The rate of DFS at 5 years was
93.8%, the freedom from distant recurrence was 99.3% and the
overall survival was 98%. Similar to the MINDACT trial, this shows
that genomic testing can identify patients with a good prognosis
without chemotherapy, despite a clinical indication for
chemotherapy.
In a similarly designed trial (RxPonder), node-positive patients
with HR+ breast cancer and a low or intermediate test result are
randomly assigned to hormone therapy with or without
chemotherapy [84]. Results of this trial will show whether it is safe
to withhold chemotherapy based on a low or intermediate test
result population despite the high-risk nodal status.WSG PlanB
In the West German Study Group Phase III PlanB Trial, 3198
clinically high-risk patients were enrolled, including 41.1% with
node-positive disease. Although originally designed to compare
two regimes of chemotherapy, after inclusion of 274 patients the
study was amended to omit chemotherapy in patients with a
low-risk OncotypeDX test result, despite their high clinical risk
[36].
In this high-risk population, 348 patients received no
chemotherapy based on a low-risk Recurrence Score of <12. At 3
years of follow-up, the disease-free survival was 98.4% in this sub-
group, indicating again that genomic subtyping can identify a clin-
ically high-risk subgroup with an excellent prognosis without
chemotherapy, although longer follow-up is warranted for definite
conclusions. Similar to the TAILORx, this study used an alternative
cut-off for low-risk scores, which needs to be considered when
interpreting the results.Clinical utility
A total of 28 studies which evaluated the clinical utility of
assays has been identified, of which 22 for OncotypeDX, four
for MammaPrint, and one for both Prosigna and Endopredict.
Almost all studies compared the (hypothetical) application of
chemotherapy for the same patient, with and without the results
of the genomic test. In general, de-escalation from chemotherapy
to no therapy or endocrine therapy alone was higher than the
escalation towards chemotherapy, which led to a decrease in
chemotherapy use for all tests. When the results were pooled
per assay, the decrease in chemotherapy was the most pro-
nounced for OncotypeDX (45.7% from chemotherapy to endo-
crine therapy alone or no adjuvant therapy) compared to
MammaPrint (32.2% decrease) (Table 3). However, these pooled
results should be interpreted carefully, since there is a large dif-
ference in the number of studies per test, the baseline patient
populations and study designs.
For OncotypeDX, three other studies evaluated the use of
chemotherapy in population studies [113–115]. Two of them
observed a decrease in chemotherapy use during the designated
years, and an increase in genomic testing [114,115]. However, no
direct relation was observed between both results. In the study
of Su et al., performed in a US medicare population between
Table 3
Clinical utility, according to test and nodal status.
Clinical utility










Drukker [85] 2014 N = 414, T1-3 49 37 4.3 29.1
Early stage breast cancer (combined LN- and LN+, other groups or not specified)
Pohl [86] 2016 N = 107, HR+ HER2 56.1 39.2 40 62
Exner [87] 2014 N = 75, grade 1 or 2, T 1-3cm, HR+
HER2
41.3 33.3 9.1 32.3
Cusumano [88] 2014 N = 194, T1-3N0-1 60.8 60.8 34.6 22.3
Subtotal MammaPrint
N = 790 52.1 42.8 17.0 32.2
OncotypeDX
Lymph node negative
Ozmen [89] 2016 N = 165, T1-3N0-1mic, HR+ HER2 55.8 37 13.7 44.6
Levine [90] 2016 N = 972, T1-4N0-1mic, HR+ HER2 22* 20.7 10.9 62.6
Leung [91] 2016 N = 146, T1-3N0-1mic, HR+ 52.1 37.7 4.3 31.6
Gligorov [92] 2015 N = 100, T1-3N0-1mic, HR+ HER2 52 25 10.9 61.2
Lee [93] 2015 N = 212, T1-3N0-1mic, HR+ 70.7 22.1 9.7 72.7
Jaafar [94] 2014 N = 47, T1-2N0, HR+ HER2 48.9 25.5 4.2 52.2
Davidson [95] 2013 N = 150, T1-3N0, HR+ HER2 41.3 31.3 17 48.4
Holt [96] 2013 N = 142, T1-3N0-1mic, HR+ 40.1 30.3 14.1 45.6
Biroschak [97] 2013 N = 50, T1-3N0, HR+ 72 70 28.6 13.9
Ademuyiwa
[98]
2011 N = 276, T1-3N0 HR+ HER2 45.3 32 22.5 56.8
Albanell [99] 2011 N = 107, T1-3N0, ER+ HER2 37 27 17.6 56.4
Lo [100] 2010 N = 89, T1-2N0, HR+ 47.2 25.9 6.5 47.6
Henry [101] 2009 N = 29, T1-3N0, HR+ 45 28 13 54
Oratz [102] 2007 N = 74, T1-3N0, HR+ 48 48 20 21.2
Early stage breast cancer (combined LN- and LN+, other groups or not specified)
Kuchel [103] 2016 N = 137, T1-3N0-1, HR+ HER2 50.4 27.7 18.2 62.3
Bargallo [104] 2014 N = 96, T1-3N0-1 ER+ HER2 48 31 16 45.7
Yamauchi
[105]
2014 N = 124, T1-3N0-1, HR+ HER2 51 24 11.5 63.5
Fried [106] 2014 N = 111, T1-3N0-1, HR+ 29.7 27.9 14.1 39.4
Cheung [107] 2014 N = 64,T1-2N0-1, HR+ HER2 61 55 16 20.5
Eiermann [108] 2013 N = 366, T1-3N0-1, HR+ HER2 57 46 25 38
De Boer [109] 2013 N = 151, T1-3N0-1, HR+ HER2 44.4 37.1 15.5 35.8
Geffen [110] 2011 N = 135, T1-2N0-1 47 36 13.9 38.1
Subtotal OncotypeDX
N = 3743 50.2 30.6 14.6 51.1
PAM50/Prosigna
Martin [111] 2015 N = 200, T1-2N0, HR+ HER2 30% 28% 12.9% 37.3%
EndoPredict
Muller [112] 2013 N = 167, T1-3N1-3, HR+ HER2 63.8% 47.7% 34% 53.2%
* Not included in pooled data, since pre-test chemotherapy also included 34% unsure.
E.J. Blok et al. / Cancer Treatment Reviews 62 (2018) 74–90 832008 and 2011, no difference in the use of chemotherapy was
observed despite an increase of assay use from 9 to 17.2% [113].
Two other studies evaluated the use of chemotherapy between
patients with and without genomic testing [116,117]. In the large
study performed by Ray et al. (n = 7004), 22% of chemotherapy
was observed in patients without testing, whereas 26% used
chemotherapy after genomic profiling. In contrast, Stemmer et al.
(n = 951) observed in a node-positive population, a 70%
chemotherapy use without testing and a 24.5% chemotherapy
use after genomic testing.
In a similar study design, Kuijer et al. observed a 10% lower rate
of chemotherapy for patients with genomic testing using Mamma-
Print [118].
Economic value
Forty-four original economic evaluations were found, of which
32 on Oncotype DX, 7 on MammaPrint, 1 on EndoPredict and 4
direct comparisons between tests (Table 4). Most evaluationscompared genomic testing to a variety of strategies without
genomic testing; four evaluations were head-to-head comparisons
between genomic policies. Of the evaluations, 5 only estimated
costs (CMAs), 1 estimated life years without QALYs (CEA) and 38
estimated QALYs (CUAs).
Methodologically, only 2 evaluations (both CMA) compared
measured outcomes between two actual patient groups with and
without genomic testing [113,119]. The remaining 42 evaluations
all used mathematical (mostly Markov) modelling to compare esti-
mated outcomes for different policies, for the same actual or hypo-
thetical group of patients. These mathematical models typically
estimated a decrease in chemotherapy (because the shift to low
risk exceeds the shift to high risk), a decrease in recurrence
(because the decrease in high risk exceeds the increase in low risk),
and an increase in life years and QALYs (due to the decrease in
recurrence and toxicity). Total health care costs may go up or
down, depending on the balance between the assay costs and sav-
ings on chemotherapy and recurrence. Three studies also included
savings on productivity [120–122].
Table 4
Economic evaluations, according to test and nodal status.







MammaPrint compared to no genomic testing
Lymph node negative
Bonastre [124] 2014 Adjuvant! Online N0 France € 2037 0.02 0.01 € 134,000 per QALY
Chen [125] 2010 Adjuvant! Online N0 US $ 1440 0.153 0.143 $ 10,000 per QALY
Exner [87] 2014 Usual care N0 HR+ HER2 NL € 3779 0.73 – Dominant
Kondo [126] 2012 Best practice N0 ER+ HER2 Japan $ 2571 0.06 0.048 $ 43,044 per QALY
Retèl [127] 2010 Adjuvant! Online N0 ER+ NL € 1130 0.24 0.2 € 4614 per QALY
Retèl [128] 2013 Adjuvant! Online N0 ER+ NL € 2401 0.62 – Dominant
Lymph node positive (or mixed)
Oestreicher
[123]
2005 Best practice N  0 stage  II pre-
menopausal
US $ 2882 0.21 – $ 13,724 per QALY (in favor of BP)
OncotypeDX compared to no genomic testing
Lymph node negative
Bacchi [129] 2010 Usual care N0 ER+ Brazil $ 794 – – Cost saving
Cosler [130] 2009 Chemotherapy +
Tamoxifen
N0 ER+ US $ 2256 0 – Dominant
Davidson [95] 2013 Usual care N0 ER+ HER2 Canada CAN$ 2188 0.33 0.31 CAN$ 6630 per QALY
Epstein [119] 2015 Usual care N0 ER+ US $ 1367 – – Cost increasing
Hannouf [131] 2012 Usual care N0 HR+ Canada CAN$ 2879 0.059 – CAN$ 48,493 per QALY
Holt [96] 2013 Usual care N0-1 ER+ UK £ 888 0.14 0.16 £ 6232 per QALY
Hornberger
[132]
2005 Usual care N0 ER+ US $ 1160 0.162 – Dominant
Hornberger
[133]
2011 Best practice N0 ER+ US $ 2028 0.086 0.0421 Dominant
Jahn [134] 2015 Adjuvant! Online N0 HR+ HER2 Austria € 2750 0.46 0.59 € 5978 per QALY
Katz [120] 2015 Usual care N0 HR+ HER2 France € 602 0.17 0.18 Dominant
Klang [135] 2010 Usual care N0 ER+ Israel $ 1828 0.17 – $ 10,770 per QALY
Kondo [136] 2008 Best practice N0 HR+ Japan $ 2516 0.097 0.083 $ 30,137 per QALY
Kondo [137] 2011 Best practice N0 ER+ Japan $ 2407 0.63 – $ 3848 per QALY
Lamond [138] 2012 Usual care N0 ER+ Canada CAN$ 2585 0.27 – CAN$ 9591 per QALY
OHTA [139] 2010 Adjuvant! Online N0 HR+ HER2 Ontario CAN$ 4168 1.3 – CAN$ 3206 per QALY
Paulden [140] 2013 Adjuvant! Online N0 HR+ HER2 Canada CAN$ 2460 0.429 0.53 CAN$ 5734 per QALY
Reed [121] 2013 Adjuvant! Online N0 ER+ US $ 1741 0.16 0.19 $ 10,788 per QALY
Smyth [141] 2015 Best practice N0 ER+ Ireland € 1361 – – Cost saving
Su [113] 2016 Usual care N0 HR+ HER2 US $ 400 – – Cost increasing
Tsoi [142] 2010 Adjuvant! Online N0 HR+ Canada CAN$ 4102 0.065 0.064 CAN$ 63,064 per QALY
Vataire [122] 2012 Usual care N0 ER+ HER2 France € 1600 0.14 0.15 Dominant
Ward [143] 2013 Usual care N0 ER+ HER2 UK £ 2575 0.1 – £ 29,502 per QALY
Yamauchi [144] 2014 Usual care N0 ER+ Japan $ 1536 0.241 – $ 6368 per QALY
Lymph node positive (or mixed)
Bargalló-Rocha
[145]
2015 Usual care N3 HR+ HER2 Mexico $ 129 – 0.068 $ 1914 per LY
Blohmer [146] 2013 Usual care N3 ER+ HER2 Germany € 561 0.06 0.06 Dominant
Hall [147] 2012 Chemotherapy N+ ER+ UK £ 860 0.16 0.15 £ 5529 per QALY
Hannouf [148] 2014 Usual care N+ HR+ post-menopausal Canada CAN$ 36.2 0.08 – CAN$ 464 per QALY
Kip [149] 2015 Usual care N1 ER+ NL € 1236 0.11 – € 11,236 per QALY
Kondo [137] 2011 Best practice N+ ER+ Japan $ 3434 0.07 – $ 49,059 per QALY
Lamond [138] 2012 Usual care N+ ER+ Canada CAN$ 864 0.06 – CAN$ 14,844 per QALY
Nerich [150] 2014 Usual care N1 ER+ HER2 France € 128 – – Cost saving
Vanderlaan
[151]
2011 Best practice N+ ER+ HER2 US $ 384 0.127 – Dominant
EndoPredict compared to no genomic testing
Lymph node positive (or mixed)
Blank [152] 2015 Best practice N  0 ER+ HER2 Germany € 3388 0.002 0.037 Dominant
Head-to-head comparisons
Mislick [153] 2014 Mammostrat vs
OncotypeDX
N0 ER+ US $ 2268 0.005 0.002 $ 453,600 per QALY (in favor of
Mammostrat)
Retèl [154] 2012 MammaPrint vs
OncotypeDX
N0 ER+ NL € 1475 0.08 0.14 Mammaprint dominant
Seguí [155] 2014 MammaPrint vs
OncotypeDX
N0 ER+ HER2 Spain € 1085 0.745 0.863 € 1457 per QALY (in favor of
Mammaprint)
Yang [156] 2012 MammaPrint vs
OncotypeDX
N0 ER+ US $ 6284 0.097 – Mammaprint dominant
84 E.J. Blok et al. / Cancer Treatment Reviews 62 (2018) 74–90Fig. 2 shows the estimated impact of genomic testing on QALYs
and costs, according to the 40 evaluations comparing genomic test-
ing to a strategy without genomic testing. The horizontal axis
shows the impact on QALYs: all studies but one [123] reported that
genomic testing resulted in better patient outcome with a positive
impact on QALYs. The vertical axis shows the impact on costs:
genomic testing was cost saving in 14 (35%) evaluations and costincreasing in 26 (65%) of the evaluations. On average, total costs
increased by 449 euro per patient with an improvement on patient
outcome of 0.16 life years and 0.20 QALYs. In general, there were
no apparent differences between the estimated outcomes for the
different genomic tests. Also, the range of costs was comparable
in node-negative and node-positive patients, but the estimated
QALY gain was larger in node-negative patients (on average, 0.24
Fig. 2. Estimated impact on costs and quality-adjusted life years (QALYs) per economic evaluation, according to test and nodal status.
E.J. Blok et al. / Cancer Treatment Reviews 62 (2018) 74–90 85versus 0.07 QALYs). Considering the improvement in patient out-
come, genomic testing was cost-effective in 36 (90%) of the evalu-
ations, i.e. below the dashed 40,000 euro-per-QALY line.Discussion
In this systematic review, we evaluated four commercially
available prognostic genomic profiles on four selected crucial
aspects. On all aspects, the tests are well-studied, with multiple
well-designed and well-performed studies available. It is apparent
that on the level of quantity, MammaPrint and especially Onco-
typeDX are more extensively studied compared to the more
recently developed Endopredict and Prosigna/PAM50 assay. At this
time of development, both OncotypeDX and MammaPrint are suit-
able assays which can be helpful in the clinical setting. However,
this review also identified some caveats which will need to be
addressed before genomic profiling can be optimally applied.
Assay development and methodology
The first topic for improvement is the identification of a sub-
group that benefits most from genomic profiling. This has already
been investigated for OncotypeDX, and to a lesser extent for Mam-
maPrint. For Prosigna and Endopredict we did not identify studies
that studied for which clinicopathological subtypes genomic profil-
ing is valuable. In general, the studies show that patients with
grade 3, PR- and a high Ki-67 have no benefit from testing, since
they are almost always high-risk. In contrast, patients with grade
1, ER+PR+ and Ki-67 <10% have no benefit from testing either, since
(almost) all of them had a low-risk result. As suggested by the
flowchart build by Allison et al., all other patients would have an
indication for genomic profiling [38]. However, most of these stud-
ies were performed in a node-negative cohort. MINDACT has
shown that despite node-positive disease, it could be considered
to withhold chemotherapy at a low genomic risk score. Therefore,
it is crucial that this test-result predicting model is validated and
adjusted in large trial cohorts like MINDACT and the WSG Plan-B
trial.Clinical validation
One of the most important (theoretical) benefits of a genomic
profiling test is the selection of patients in which the treatment
with adjuvant chemotherapy will have a significant benefit. Cur-
rently, this task of genomic profiles is mainly performed by their
prognostic capacities; i.e. the ability to identify patients with a
poor prognosis for recurrence or survival. However, the results of
the studies in this review, especially that of MINDACT, show that
this does not automatically translate into a benefit of chemother-
apy for these higher-risk patients. So far, no genomic test has
shown it’s predictive capacities in a prospective trial design. The
only evidence for a predictive value was obtained in two prospec-
tive studies conducted on archived tissue (prospective-
retrospective design) in which the OncotypeDX retrospectively
identified patients that benefit more from chemotherapy to which
they were randomly allocated [62,65].Clinical utility
Currently, the clinical consensus on adjuvant chemotherapy is
that we are most likely over-treating our patients, since we are
not capable of identifying patients that will or will not benefit from
chemotherapy using the current clinicopathological parameters
[157,158]. It is no surprise that the studies evaluating the clinical
utility of genomic profiling especially show a reduction in
chemotherapy use. However, absolute numbers should be inter-
preted carefully, since some tests are less frequently studied than
others, which increases the risk of bias and skewed data. Interest-
ingly, in retrospective population-based cohorts, implementation
of genomic testing did not lead to a reduction in chemotherapy
use [113–115]. This is in accordance with Petkov et al., who retro-
spectively matched OncotypeDX use with SEER registry data for
over 40,000 patients [159]. Although the risk categories were
indeed prognostic for five-year breast-cancer-specific mortality in
this real-life population, patients with node negative, HR+, HER2-
breast cancer which underwent testing (n = 40,134, 22.7%
chemotherapy) had no lower chemotherapy use compared to
86 E.J. Blok et al. / Cancer Treatment Reviews 62 (2018) 74–90patients that were not tested (n = 144,056, 22.2% chemotherapy).
Therefore, conclusions about genomic profiling leading to decrease
in chemotherapy cannot be drawn from these analyses.
Economic value
Our review of economic evaluations identified 44 original pub-
lications, where earlier reviews included at most 11 or 18 pub-
lished evaluations [160,161]. Except for the oldest evaluation
[123], all studies reported improved patient outcome in terms of
QALYs. Despite estimated savings on chemotherapy, recurrence
and productivity, a small majority (65%) of the evaluations esti-
mated that genomic testing resulted in an increase in total costs.
Nevertheless, most evaluations (90%) estimated that genomic test-
ing is cost-effective, with costs that are acceptable in relation to
patient outcome. These economic results should be considered
with caution. Firstly, the separate evaluations should not be inter-
preted as independent primary studies, because the models obtain
their data from overlapping sources: mostly the diagnostic data are
taken from the landmark trials and then applied to the care pat-
terns of a particular country. Secondly, the economic studies gen-
erally evaluate the use of genomic testing in large groups of
women, instead of trying to combine genomic profiling with other
prognostic factors to identify those individual women for whom
genomic testing does not have sufficient added value or could even
be harmful. And thirdly, compared to trials, economic evaluations
are more likely to suffer from publication bias.
Future perspectives
In the near future, trial results from RxPonder, TAILORx and
WSG plan-B will become available, contributing to understanding
the role of OncotypeDX in daily practice in both node-positive
and node-negative disease. Furthermore, subgroup analyses and
long-term follow-up of MINDACT will follow later and help define
the place for MammaPrint in the diagnostic process, and the long-
term safety of withholding chemotherapy in high-risk patients,
based on a low-risk test result. The OPTIMA trial, randomizing
high-risk ER+HER2- patients between standard chemotherapy, or
treatment directed by Prosigna test-results will be the first trial
to show level A evidence for the Prosigna/PAM50 test.
Another interesting development is the use of gene expression
assays for the indication of endocrine therapy. Very recently, a ret-
rospective analysis from Sweden identified an ultra-low category
within the low-risk category of MammaPrint (15% of all patients,
26% of low-risk patients) [162]. Patients with this ultra-low risk
score (n = 98) had a breast cancer specific survival of 94% at 20
years without any adjuvant therapy, and 97% at 20 years with just
2 years of tamoxifen, whereas 5+ years of therapy is the current
standard for these patients [163]. Upon validation, these findings
could lead to the implementation of gene expression assays in
the indication for adjuvant endocrine therapy.
Conclusions
In summary, in this systematic review we have evaluated the
four most frequently used assays in Europe on four relevant
aspects. Regarding the amount of evidence, there is a clear separa-
tion between the more established MammaPrint and OncotypeDX
on one hand, and the newer Prosigna and Endopredict on the other
hand. Comparing MammaPrint and OncotypeDX, both assays have
shown to be a useful prognostic tests which could lead to a reduc-
tion in chemotherapy use, with in general a favourable cost-benefit
ratio. Both the MammaPrint and OncotypeDX have shown in
prospective trials that a patient with a low-risk result can safely
forego chemotherapy, despite clinical risk factors. In contrast, thebenefit of chemotherapy with a high-risk test result has so far only
been shown for OncotypeDX, albeit in retrospective analyses of
archived tissue of prospective trials. Therefore, there is still a need
for further prospective studies on all evaluated assays.Conflicts of interest
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